|
11 Companies |
|
3 Products |
|
3 Products |
|
2 Mechanisms of Action |
|
0 Trials |
|
57 News |
|
| 12» |
- ||| Trial completion, Trial completion date, Trial primary completion date: ProF-001_Phase IIa (clinicaltrials.gov) - Mar 14, 2019
P2a, N=84, Completed, Sponsor: ProFem GmbH
Recruiting --> Completed | Trial completion date: Jan 2018 --> Jul 2018 | Trial primary completion date: Jan 2018 --> Jul 2018
- || NN1213 / Novo Nordisk
Enrollment change, Trial withdrawal: Efficacy, Safety LactiSal 1% Gel, LactSal 50 mg, Clotrimazole 100 mg Tablet in Treatment Vulvovaginal Candidiasis (clinicaltrials.gov) - Mar 8, 2019
P3, N=0, Withdrawn, Sponsor: Medinova AG
Recruiting --> Completed | Trial completion date: Jan 2018 --> Jul 2018 | Trial primary completion date: Jan 2018 --> Jul 2018 N=300 --> 0 | Not yet recruiting --> Withdrawn
- | oral amphotericin B (MAT2203) / Matinas
Enrollment change, Trial withdrawal: Efficacy and Safety of Oral Encochleated Amphotericin B (CAMB) in the Treatment of Fluconazole-Resistant Vulvovaginal Candidiasis (clinicaltrials.gov) - Mar 8, 2019
P2, N=0, Withdrawn, Sponsor: Matinas BioPharma Nanotechnologies, Inc.
N=300 --> 0 | Not yet recruiting --> Withdrawn N=16 --> 0 | Not yet recruiting --> Withdrawn
- | oral amphotericin B (MAT2203) / Matinas
Trial completion date, Trial initiation date, Trial primary completion date: Efficacy and Safety of Oral Encochleated Amphotericin B (CAMB) in the Treatment of Fluconazole-Resistant Vulvovaginal Candidiasis (clinicaltrials.gov) - Jan 7, 2019
P2, N=16, Not yet recruiting, Sponsor: Matinas BioPharma Nanotechnologies, Inc.
N=16 --> 0 | Not yet recruiting --> Withdrawn Trial completion date: Jun 2019 --> Dec 2020 | Initiation date: Dec 2018 --> Dec 2019 | Trial primary completion date: Jun 2019 --> Dec 2020
- | otesaconazole (VT-1161) / Mycovia Pharma
Phase classification: A Study to Evaluate the Efficacy and Safety of Oral VT-1161 in Patients With Acute Vaginal Candidiasis (Yeast Infection) (clinicaltrials.gov) - Jul 6, 2018
P2a, N=55, Completed, Sponsor: Viamet
Trial completion date: Jun 2019 --> Dec 2020 | Initiation date: Dec 2018 --> Dec 2019 | Trial primary completion date: Jun 2019 --> Dec 2020 Phase classification: P2 --> P2a
- NN1213 / Novo Nordisk
Trial termination: Effect of Saccharomyces Cerevisiae on Vulvo-vaginal Candidiasis (clinicaltrials.gov) - Jun 13, 2018
P=N/A, N=80, Terminated, Sponsor: Lesaffre International
Phase classification: P2 --> P2a Recruiting --> Terminated; Recruitment difficulties
- | oral amphotericin B (MAT2203) / Matinas
Trial completion date, Trial primary completion date: Efficacy and Safety of Oral Encochleated Amphotericin B (CAMB) in the Treatment of Fluconazole-Resistant Vulvovaginal Candidiasis (clinicaltrials.gov) - Jun 12, 2018
P2, N=16, Not yet recruiting, Sponsor: Matinas BioPharma Nanotechnologies, Inc.
Recruiting --> Terminated; Recruitment difficulties Trial completion date: Feb 2019 --> Jun 2019 | Trial primary completion date: Feb 2019 --> Jun 2019
- Rezzayo (rezafungin for injection) / Cidara Therap, Mundipharma, Melinta Therap
Trial completion date, Trial initiation date: Non-Interventional Extension to Investigate Recurrence of Vulvovaginal Candidiasis and Candida Colonization (clinicaltrials.gov) - Mar 3, 2018
P=N/A, N=32, Completed, Sponsor: Cidara Therapeutics Inc.
Trial completion date: Feb 2019 --> Jun 2019 | Trial primary completion date: Feb 2019 --> Jun 2019 Trial completion date: Mar 2017 --> Mar 2017 | Initiation date: Aug 2016 --> Aug 2016
- ||||| Trial initiation date, Trial primary completion date: Efficacy, Safety LactiSal 1% Gel, LactSal 50 mg, Clotrimazole 100 mg Tablet in Treatment Vulvovaginal Candidiasis (clinicaltrials.gov) - Dec 14, 2017
P3, N=300, Not yet recruiting, Sponsor: Medinova AG
Trial completion date: Mar 2017 --> Mar 2017 | Initiation date: Aug 2016 --> Aug 2016 Initiation date: May 2017 --> Dec 2018 | Trial primary completion date: May 2018 --> Dec 2019
- | oral amphotericin B (MAT2203) / Matinas
Trial initiation date, Trial primary completion date: Efficacy and Safety of Oral Encochleated Amphotericin B (CAMB) in the Treatment of Fluconazole-Resistant Vulvovaginal Candidiasis (clinicaltrials.gov) - Dec 7, 2017
P2, N=16, Not yet recruiting, Sponsor: Matinas BioPharma Nanotechnologies, Inc.
Initiation date: May 2017 --> Dec 2018 | Trial primary completion date: May 2018 --> Dec 2019 Initiation date: Aug 2017 --> Aug 2018 | Trial primary completion date: Feb 2018 --> Feb 2019
- | Trial primary completion date: ProF-001_Phase IIa (clinicaltrials.gov) - Sep 25, 2017
P2a, N=84, Recruiting, Sponsor: ProFem GmbH
Initiation date: Aug 2017 --> Aug 2018 | Trial primary completion date: Feb 2018 --> Feb 2019 Trial primary completion date: Aug 2017 --> Jan 2018
- | oral amphotericin B (MAT2203) / Matinas
Trial completion, Enrollment change: Safety and Efficacy of Oral Encochleated Amphotericin B (CAMB/MAT2203) in the Treatment of Vulvovaginal Candidiasis (VVC) (clinicaltrials.gov) - Aug 10, 2017
P2, N=137, Completed, Sponsor: Matinas BioPharma Nanotechnologies, Inc.
Trial primary completion date: Aug 2017 --> Jan 2018 Recruiting --> Completed | N=75 --> 137
- | TOL-463 / Toltec Pharma
Trial completion: TOL-463 Phase 2 Study for Vaginitis (clinicaltrials.gov) - Jul 23, 2017
P2, N=106, Completed, Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)
Recruiting --> Completed | N=75 --> 137 Active, not recruiting --> Completed
- | Rezzayo (rezafungin for injection) / Cidara Therap, Mundipharma, Melinta Therap
Trial completion: Non-Interventional Extension to Investigate Recurrence of Vulvovaginal Candidiasis and Candida Colonization (clinicaltrials.gov) - Jun 4, 2017
P=N/A, N=32, Completed, Sponsor: Cidara Therapeutics Inc.
Active, not recruiting --> Completed Active, not recruiting --> Completed
- | oral amphotericin B (MAT2203) / Matinas
New P2 trial: Efficacy and Safety of Oral Encochleated Amphotericin B (CAMB) in the Treatment of Fluconazole-Resistant Vulvovaginal Candidiasis (clinicaltrials.gov) - May 30, 2017
P2, N=16, Not yet recruiting, Sponsor: Matinas BioPharma Nanotechnologies, Inc.
- | TOL-463 / Toltec Pharma
Enrollment closed, Trial primary completion date: TOL-463 Phase 2 Study for Vaginitis (clinicaltrials.gov) - May 19, 2017
P2, N=106, Active, not recruiting, Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)
Active, not recruiting --> Completed Recruiting --> Active, not recruiting | Trial primary completion date: Jan 2017 --> Jun 2017
- Rezzayo (rezafungin for injection) / Cidara Therap, Mundipharma, Melinta Therap
Enrollment closed, Enrollment change: Non-Interventional Extension to Investigate Recurrence of Vulvovaginal Candidiasis and Candida Colonization (clinicaltrials.gov) - Mar 27, 2017
P=N/A, N=32, Active, not recruiting, Sponsor: Cidara Therapeutics Inc.
Recruiting --> Active, not recruiting | Trial primary completion date: Jan 2017 --> Jun 2017 Enrolling by invitation --> Active, not recruiting | N=125 --> 32
- Enrollment change, Trial termination, Trial primary completion date: Effect of Saccharomyces Cerevisiae on Improving the Effectiveness of Conventional Treatment of Vulvo-vaginal Candidiasis (clinicaltrials.gov) - Dec 5, 2016
P=N/A, N=22, Terminated, Sponsor: Lesaffre International
Enrolling by invitation --> Active, not recruiting | N=125 --> 32 N=60 --> 22 | Recruiting --> Terminated | Trial primary completion date: Dec 2015 --> Jun 2015; Recruitment difficulties
- | oral amphotericin B (MAT2203) / Matinas
New P2 trial: Safety and Efficacy of Oral Encochleated Amphotericin B (CAMB/MAT2203) in the Treatment of Vulvovaginal Candidiasis (VVC) (clinicaltrials.gov) - Nov 22, 2016
P2, N=75, Recruiting, Sponsor: Matinas BioPharma Nanotechnologies, Inc.
- |||| Trial completion, Phase classification: Safety, Tolerability, Immunogenicity and Efficacy of NDV-3A Vaccine in Preventing Recurrent Vulvovaginal Candidiasis (clinicaltrials.gov) - Sep 22, 2016
P1b/2a, N=188, Completed, Sponsor: NovaDigm Therapeutics, Inc.
N=60 --> 22 | Recruiting --> Terminated | Trial primary completion date: Dec 2015 --> Jun 2015; Recruitment difficulties Active, not recruiting --> Completed | Phase classification: P1/2 --> P1b/2a
- |||| clotrimazole topical / Generic mfg.
Trial completion: Comparative Efficacy Study of 10 mg Dequalinium Chloride (Fluomizin) in the Treatment of Vulvovaginal Candidiasis (clinicaltrials.gov) - Sep 15, 2016
P4, N=150, Completed, Sponsor: Medinova AG
Active, not recruiting --> Completed | Phase classification: P1/2 --> P1b/2a Recruiting --> Completed
- ||| Rezzayo (rezafungin for injection) / Cidara Therap, Mundipharma, Melinta Therap
New trial: Non-Interventional Extension to Investigate Recurrence of Vulvovaginal Candidiasis and Candida Colonization (clinicaltrials.gov) - Sep 2, 2016
P=N/A, N=125, Enrolling by invitation, Sponsor: Cidara Therapeutics Inc.
- | TOL-463 / Toltec Pharma
New P2 trial: TOL-463 Phase 2 Study for Vaginitis (clinicaltrials.gov) - Aug 15, 2016
P2, N=90, Recruiting, Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)
- ||| New trial: Effect of Saccharomyces Cerevisiae on Vulvo-vaginal Candidiasis (clinicaltrials.gov) - Aug 9, 2016
P=N/A, N=80, Recruiting, Sponsor: Lesaffre International
- New P1 trial: COMPRIGEL: Study Evaluating the Optimal Dosage for Equivalence Between Lcr Regenerans (clinicaltrials.gov) - Apr 6, 2016
P1, N=34, Completed, Sponsor: Biose
- ||||||| Trial completion, Trial primary completion date, Head-to-Head: GYNOCANS: Study of the Efficacy and Tolerance of Intra-vaginal Treatment With a Total Freeze-dried Culture of Lcr Regenerans (clinicaltrials.gov) - Mar 25, 2016
P3, N=350, Completed, Sponsor: Probionov
Recruiting --> Completed Active, not recruiting --> Completed | Trial primary completion date: May 2014 --> Feb 2016
- Trial completion: VAST: Comparing NAAT Testing to Standard Methods for the Diagnosis of Vaginitis (clinicaltrials.gov) - Jan 27, 2016
P=N/A, N=300, Completed, Sponsor: University of Pittsburgh
Active, not recruiting --> Completed | Trial primary completion date: May 2014 --> Feb 2016 Recruiting --> Completed
- ||||| Enrollment closed, Head-to-Head: GYNOCANS: Study of the Efficacy and Tolerance of Intra-vaginal Treatment With a Total Freeze-dried Culture of Lcr Regenerans (clinicaltrials.gov) - Dec 17, 2015
P3, N=322, Active, not recruiting, Sponsor: Probionov
Recruiting --> Completed Recruiting --> Active, not recruiting
- |||| fluconazole oral / Generic mfg.
Trial completion, Trial primary completion date: Clotrimazole Vaginal Tablet vs Fluconazole for Severe Vulvovaginal Candidiasis (clinicaltrials.gov) - Oct 20, 2015
P4, N=240, Completed, Sponsor: Peking University Shenzhen Hospital
Recruiting --> Active, not recruiting Recruiting --> Completed | Trial primary completion date: May 2015 --> Sep 2015
- || Trial primary completion date: Effect of Saccharomyces Cerevisiae on Improving the Effectiveness of Conventional Treatment of Vulvo-vaginal Candidiasis (clinicaltrials.gov) - Sep 24, 2015
P=N/A, N=60, Recruiting, Sponsor: Lesaffre International
Recruiting --> Completed | Trial primary completion date: May 2015 --> Sep 2015 Trial primary completion date: Jun 2015 --> Dec 2015
- ||| Enrollment closed, Trial primary completion date: Safety, Tolerability, Immunogenicity and Efficacy of NDV-3A Vaccine in Preventing Recurrent Vulvovaginal Candidiasis (clinicaltrials.gov) - May 27, 2015
P1/2, N=188, Active, not recruiting, Sponsor: NovaDigm Therapeutics, Inc.
Trial primary completion date: Jun 2015 --> Dec 2015 Recruiting --> Active, not recruiting | Trial primary completion date: Dec 2014 --> May 2015
- ||| Trial completion, Enrollment change, Trial initiation date, Trial primary completion date: Observational Program Neo-Penotran (clinicaltrials.gov) - Apr 28, 2015
P=N/A, N=13024, Completed, Sponsor: Bayer
Recruiting --> Active, not recruiting | Trial primary completion date: Dec 2014 --> May 2015 Recruiting --> Completed | N=20000 --> 13024 | Initiation date: Jan 2011 --> Oct 2010 | Trial primary completion date: Dec 2015 --> Dec 2011
- Trial completion, Trial primary completion date: Epidemiological Study About the Evolution of Patients Treated for an Acute Episode of Vulvovaginal Candidiasis (clinicaltrials.gov) - Mar 25, 2015
P4, N=56, Completed, Sponsor: Instituto Palacios
Recruiting --> Completed | N=20000 --> 13024 | Initiation date: Jan 2011 --> Oct 2010 | Trial primary completion date: Dec 2015 --> Dec 2011 Recruiting --> Completed | Trial primary completion date: Jun 2015 --> Mar 2015
- ||| Clinical: Effect of Saccharomyces Cerevisiae on Improving the Effectiveness of Conventional Treatment of Vulvo-vaginal Candidiasis (clinicaltrials.gov) - Jan 26, 2015
P=N/A, N=60, Recruiting, Sponsor: Lesaffre International
- |||| otesaconazole (VT-1161) / Mycovia Pharma
Trial completion, Trial primary completion date: A Study to Evaluate the Efficacy and Safety of Oral VT-1161 in Patients With Acute Vaginal Candidiasis (Yeast Infection) (clinicaltrials.gov) - Dec 25, 2014
P2, N=55, Completed, Sponsor: Viamet Pharmaceuticals, Inc.
Recruiting --> Completed | Trial primary completion date: Jun 2015 --> Mar 2015 Active, not recruiting --> Completed | Trial primary completion date: Aug 2014 --> Dec 2014
- |||| clotrimazole topical / Generic mfg.
Enrollment open: Comparative Efficacy Study of 10 mg Dequalinium Chloride (Fluomizin) in the Treatment of Vulvovaginal Candidiasis (clinicaltrials.gov) - Nov 7, 2014
P4, N=150, Recruiting, Sponsor: Medinova AG
Active, not recruiting --> Completed | Trial primary completion date: Aug 2014 --> Dec 2014 Not yet recruiting --> Recruiting
- | New P4 trial: Epidemiological Study About the Evolution of Patients Treated for an Acute Episode of Vulvovaginal Candidiasis (clinicaltrials.gov) - Sep 28, 2014
P4, N=60, Recruiting, Sponsor: Instituto Palacios
- || New P3 trial, Head-to-Head: GYNOCANS: Study of the Efficacy and Tolerance of Intra-vaginal Treatment With a Total Freeze-dried Culture of Lcr Regenerans (clinicaltrials.gov) - Sep 28, 2014
P3, N=322, Recruiting, Sponsor: Probionov
- ||||| clotrimazole topical / Generic mfg.
New P4 trial: Comparative Efficacy Study of 10 mg Dequalinium Chloride (Fluomizin) in the Treatment of Vulvovaginal Candidiasis (clinicaltrials.gov) - Sep 19, 2014
P4, N=150, Not yet recruiting, Sponsor: Medinova AG
- |||| fluconazole oral / Generic mfg.
Enrollment open: Clotrimazole Vaginal Tablet vs Fluconazole for Severe Vulvovaginal Candidiasis (clinicaltrials.gov) - Jul 8, 2014
P4, N=240, Recruiting, Sponsor: Peking University Shenzhen Hospital
Not yet recruiting --> Recruiting Not yet recruiting --> Recruiting
- ||||| fluconazole oral / Generic mfg.
New P4 trial: Clotrimazole Vaginal Tablet vs Fluconazole for Severe Vulvovaginal Candidiasis (clinicaltrials.gov) - Jul 4, 2014
P4, N=240, Not yet recruiting, Sponsor: Peking University Shenzhen Hospital
- Trial completion: RVMM Study: Study of the Microbiota, Metabolome, and Environmental Toxins in Relation to Reproductive Health in Rwandan Women (clinicaltrials.gov) - May 28, 2014
P0, N=30, Completed, Sponsor: Western University, Canada
Not yet recruiting --> Recruiting Not yet recruiting --> Completed
- TOL-463 / Toltec Pharma
Trial completion: Evaluation of Intravaginal Gel and Ovule Formulations of TOL-463 (clinicaltrials.gov) - May 14, 2014
P1, N=26, Completed, Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)
Not yet recruiting --> Completed Active, not recruiting --> Completed
- || Secnizol DS (secnidazole) / Incepta Pharma
New P3 trial: Safety and Clinical and Microbiological Efficacy of the Combination of Fluconazole and Secnidazole for the Treatment of Symptomatic Vaginal Discharge (clinicaltrials.gov) - Apr 9, 2014
P3, N=118, Completed, Sponsor: Universidad Nacional de Colombia
- | otesaconazole (VT-1161) / Mycovia Pharma
Enrollment closed: A Study to Evaluate the Efficacy and Safety of Oral VT-1161 in Patients With Acute Vaginal Candidiasis (Yeast Infection) (clinicaltrials.gov) - Mar 13, 2014
P2, N=48, Active, not recruiting, Sponsor: Viamet Pharmaceuticals, Inc.
Active, not recruiting --> Completed Recruiting --> Active, not recruiting
- Trial completion: VCAT: Management of Vaginal Complaints: A Pilot Study Within a Practice-Based Research Network (clinicaltrials.gov) - Jan 6, 2014
P0, N=46, Completed, Sponsor: Agency for Healthcare Research and Quality (AHRQ)
Recruiting --> Active, not recruiting Not yet recruiting --> Completed
- Trial completion: Topical Metronidazole and Miconazole Co-formulated Vaginal Suppositories for Preventing Vaginal Infections in HIV-seronegative Women (clinicaltrials.gov) - Oct 30, 2013
P2, N=234, Completed, Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)
Not yet recruiting --> Completed Active, not recruiting --> Completed
- TOL-463 / Toltec Pharma
Enrollment change: Evaluation of Intravaginal Gel and Ovule Formulations of TOL-463 (clinicaltrials.gov) - Oct 23, 2013
P1, N=26, Active, not recruiting, Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)
Active, not recruiting --> Completed N=40 --> 26
- TOL-463 / Toltec Pharma
Enrollment closed: Evaluation of Intravaginal Gel and Ovule Formulations of TOL-463 (clinicaltrials.gov) - Oct 23, 2013
P1, N=26, Active, not recruiting, Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)
N=40 --> 26 Recruiting --> Active, not recruiting
- ||||| New P1/2 trial: Safety, Tolerability, Immunogenicity and Efficacy of NDV-3A Vaccine in Preventing Recurrent Vulvovaginal Candidiasis (clinicaltrials.gov) - Aug 18, 2013
P1/2, N=189, Recruiting, Sponsor: NovaDigm Therapeutics, Inc.